Responding more frequently to MiniMed Smart MDI alerts linked to better glucose outcomes for people with diabetes
PR Newswire•05/10/2026•07:08 ET
3
Key Highlights
- ➤Smart MDI users had 8.1 points more Time in Range and 0.6 points lower HbA1c
- ➤More than 5,500 real-world users showed a 9.4-point Time in Range difference
- ➤Responding to at least 28% of alerts was associated with improved HbA1c
- ➤Smart MDI met its primary endpoint and was non-inferior to MDI plus CGM
- ➤No severe hypoglycemia or diabetic ketoacidosis occurred in the Smart MDI arm
Expert Statements
Que Dallara, CEO of MiniMed
“People managing diabetes with multiple daily injections are making insulin decisions all day, every day. MiniMed Go is designed to lighten that load by remembering, reminding, and recommending when it matters. The goal is to help them achieve better outcomes with less burden. That's the promise of the MiniMed Go smart MDI system”
Laurent Crenier, MD, PhD, Head of the Endocrinology Department at HUB - Hôpital Erasme in Brussels
“These findings show a clear association between responding to Smart MDI alerts and better glucose outcomes. For people on multiple daily injections, that can mean more time in range with less day-to-day mental burden”
Responding more frequently to MiniMed Smart MDI alerts linked to better glucose outcomes for people with diabetes PR Newswire
Six-month randomized trial found 8.1 percentage points more Time in Range and 0.6 percentage points lower HbA1c among higher responders.
Get started
Create a free account to read the full story.